| Year |
Citation |
Score |
| 2019 |
Avasarala S, Wu PY, Khan SQ, Yanlin S, Van Scoyk M, Bao J, Di Lorenzo A, David O, Bedford MT, Gupta V, Winn RA, Bikkavilli RK. PRMT6 promotes lung tumor progression via the alternate activation of tumor-associated macrophages. Molecular Cancer Research : McR. PMID 31619507 DOI: 10.1158/1541-7786.Mcr-19-0204 |
0.37 |
|
| 2019 |
Panni RZ, Herndon JM, Zuo C, Hegde S, Hogg GD, Knolhoff BL, Breden MA, Li X, Krisnawan VE, Khan SQ, Schwarz JK, Rogers BE, Fields RC, Hawkins WG, Gupta V, et al. Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. Science Translational Medicine. 11. PMID 31270275 DOI: 10.1126/Scitranslmed.Aau9240 |
0.437 |
|
| 2018 |
Schmid MC, Khan SQ, Kaneda MM, Pathria P, Shepard R, Louis TL, Anand S, Woo G, Leem C, Faridi MH, Geraghty T, Rajagopalan A, Gupta S, Ahmed M, Vazquez-Padron RI, et al. Integrin CD11b activation drives anti-tumor innate immunity. Nature Communications. 9: 5379. PMID 30568188 DOI: 10.1038/S41467-018-07387-4 |
0.413 |
|
| 2018 |
Khan SQ, Khan I, Gupta V. CD11b Activity Modulates Pathogenesis of Lupus Nephritis. Frontiers in Medicine. 5: 52. PMID 29600248 DOI: 10.3389/Fmed.2018.00052 |
0.421 |
|
| 2018 |
Avasarala S, Wu P, Khan SQ, Scoyk MV, Su Y, David O, Gupta V, Bedford MT, Winn RA, Bikkavilli RK. Abstract 138: PRMT6 promotes lung tumor growth via the modulation of macrophage M2 polarization Cancer Research. 78: 138-138. DOI: 10.1158/1538-7445.Am2018-138 |
0.348 |
|
| 2018 |
Geraghty T, Rajagopalan A, Khan S, Varner J, Gupta V. Abstract 137: Pharmacologic activation of integrin CD11b as a novel therapeutic strategy against lung cancer Cancer Research. 78: 137-137. DOI: 10.1158/1538-7445.Am2018-137 |
0.367 |
|
| 2017 |
Faridi MH, Khan SQ, Zhao W, Lee HW, Altintas MM, Zhang K, Kumar V, Armstrong AR, Carmona-Rivera C, Dorschner JM, Schnaith AM, Li X, Ghodke-Puranik Y, Moore E, Purmalek M, et al. CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus. The Journal of Clinical Investigation. PMID 28263189 DOI: 10.1172/Jci88442 |
0.374 |
|
| 2017 |
Khan SQ, Faridi MH, Khaliqdina SJ, Barbosa AJ, Varner JA, Gupta V. Abstract B03: Integrin agonists reduce infiltration of tumor-associated macrophages to promote T-cell mediated anti-tumor immunity Cancer Immunology Research. 5. DOI: 10.1158/2326-6074.Tumimm16-B03 |
0.478 |
|
| 2016 |
Khan SQ, Faridi MH, Ruffell B, Lopez AMS, Jehangir S, Barbosa AJ, Torroella-Kouri M, Coussens LM, Varner J, Gupta V. Abstract A17: An integrin agonist suppresses breast cancer by reducing CD11b+ leukocytes, promoting anti-tumor immunity Cancer Research. 76. DOI: 10.1158/1538-7445.Tme16-A17 |
0.411 |
|
| 2015 |
Lee HW, Khan SQ, Faridi MH, Wei C, Tardi NJ, Altintas MM, Elshabrawy HA, Mangos S, Quick KL, Sever S, Reiser J, Gupta V. A Podocyte-Based Automated Screening Assay Identifies Protective Small Molecules. Journal of the American Society of Nephrology : Jasn. PMID 25858967 DOI: 10.1681/Asn.2014090859 |
0.307 |
|
| 2014 |
Khan SQ, Guo L, Cimbaluk DJ, Elshabrawy H, Faridi MH, Jolly M, George JF, Agarwal A, Gupta V. A Small Molecule β2 Integrin Agonist Improves Chronic Kidney Allograft Survival by Reducing Leukocyte Recruitment and Accompanying Vasculopathy. Frontiers in Medicine. 1: 45. PMID 25593918 DOI: 10.3389/Fmed.2014.00045 |
0.331 |
|
| 2013 |
Khan SQ, Tsai MS, Schreiber TH, Wolf D, Deyev VV, Podack ER. Cloning, expression, and functional characterization of TL1A-Ig. Journal of Immunology (Baltimore, Md. : 1950). 190: 1540-50. PMID 23319737 DOI: 10.4049/Jimmunol.1201908 |
0.536 |
|
| 2011 |
Schreiber TH, Khan SQ, Podack ER. Response to Taraban, Ferdinand, and Al-Shamkhani Journal of Clinical Investigation. 121: 465. DOI: 10.1172/Jci46113 |
0.595 |
|
| Show low-probability matches. |